Bikbov, Mukharram M.,
Kazakbaeva, Gyulli M.,
Holz, Frank G.,
Panda-Jonas, Songhomitra,
Gilemzianova, Leisan I.,
Khakimov, Dinar A.,
Jonas, Jost B. (2023) with pathological myopia. Methods: The clinical, monocentre, open-label,
multiple-dose, phase-1 study included
Markelov, V.A.,
Korytina, G.F.,
Aznabaeva, Y.G.,
Gibadullin, I.A.,
Akhmadishina, L.Z.,
Nasibullin, T.R.,
Kochetova, O.V.,
Avzaletdinov, A.M.,
Zagidullin, N. Sh. (2024) prognostic model was constructed based on the
multiple regression and ROC analyses. The model included
Korytina, G.F.,
Akhmadishina, L.Z.,
Markelov, V.A.,
Nasibullin, T.R.,
Aznabaeva, Y.G.,
Kochetova, O.V.,
Khusnutdinova, N.N.,
Larkina, A.P.,
Zagidullin, N. Sh.,
Victorova, T.V. (2024) cascades associated with cellular senescence and apoptosis.
Multiple regression and ROC analysis revealed a
Kazantseva, A.V.,
Davydova, Yu. D.,
Enikeeva, R.F.,
Yakovleva, D.V.,
Mustafin, R.N.,
Lobaskova, M.M.,
Malykh, S.B.,
Khusnutdinova, E.K. (2023) -measured aggression in young adults from the Volga-Ural region (VUR) of Russia. Initially, a series of
multiple linear
Yuan, Yue,
Han, Xuejie,
Zhao, Xinbo,
Zhang, Haiyu,
Vinograd, Asiia,
Bi, Xin,
Duan, Xiaoxu,
Cao, Yukai,
Gao, Qiang,
Song, Jia,
Sheng, Li,
Li, Yue (2024) -coding RNAs (lncRNAs), involve in the progress of
multiple cardiovascular diseases. However, their potential
Изменения иммунной системы в патогенезе нейрофиброматоза 1-го типа the oncosuppressor neurofibromin. The disease has a specific progressive course with
multiple neurofibromas
are
multiple subcutaneous and cutaneous neurofibromas, age spots, skeletal abnormalities, mental retardation
Kazantseva, A.V.,
Davydova, Yu. D.,
Enikeeva, R.F.,
Mustafin, R.N.,
Lobaskova, M.M.,
Malykh, S.B.,
Khusnutdinova, E.K. (2022) and individual differences in depression level in the studied sample. Nevertheless,
multiple regression analysis
Shnayder, N.A.,
Grechkina, V.V.,
Khasanova, A.K.,
Bochanova, E.N.,
Dontceva, E.A.,
Petrova, M.M.,
Asadullin, A.R.,
Shipulin, G.A.,
Altynbekov, K.S.,
Al-Zamil, M.,
Nasyrova, R.F. (2023) -modifying therapy for
multiple tumors, neurodegenerative diseases (Huntington’s disease, Parkinson’s disease